Skip to content

Acceptability and Tolerance Study of a Plant-based Tube Feed

Acceptability (including Gastrointestinal Tolerance and Compliance) of a Plant Based High Energy Adult Enteral Formula

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06209593
Enrollment
15
Registered
2024-01-17
Start date
2024-01-05
Completion date
2024-09-03
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition Disorders

Brief summary

This is a single arm, prospective, multi-centre study to evaluate the gastrointestinal tolerance and compliance over a 7-day period with a plant based tube feed.

Detailed description

Enterally fed adults who are assessed by the Health Care Professional/dietitian as requiring an adult plant- based high-energy, enteral formula will be recruited. Data from 15 participants are required in order to submit an application to the UK Advisory Committee on Borderline Substances (ACBS) for product registration

Interventions

DIETARY_SUPPLEMENTCompleat plant protein tube feed

Patients on a tube feed will act as their own control and switch to new tube feed.

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients 16 years and over and adults requiring a plant- based enteral tube feed (taking 50% or more of energy needs from their feeding tube) as part of their dietary management for disease related malnutrition * Patients well-established and stable on current polymeric enteral tube feed. * Willingly given, written, informed consent from patient

Exclusion criteria

* Inability to comply with the study protocol, in the opinion of the investigator * Under 16 years of age * Patients on total parenteral nutrition * Known food allergies to any ingredients including patients who have an allergy to milk protein e.g IgE and non- mediated as product contains traces of milk and allergy to peanuts due to the pea protein * Patients with significant renal or hepatic impairment * Participation in another interventional study within 2 weeks of this study. * Patients with known or suspected ileus or mechanical bowel obstruction

Design outcomes

Primary

MeasureTime frameDescription
Baseline assessment and daily recording during intervention up to day 7 measuring Gastrointestinal tolerance7 daysDiarrhoea, constipation, reflux, vomiting, wind, boating

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026